Аңдатпа
Experts predict more than 35 million new cases of cancer in 2050, a 77 per cent increase from 2022. A similar upward trend in cancer incidence is characteristic of the RoK. Mortality trends compared to incidence trends may indicate improved treatment. If mortality rates are falling while incidence rates are rising, this may reflect the availability of more effective treatments. The combination of cardiovascular disease with oncopathology is of particular relevance in recent times. The risk of mortality from cardiovascular disease increases with age and increases in cancer survivors over time.Objective: Comparative assessment of the clinical and functional state of the cardiovascular system in patients with and without a first diagnosis of liver cancer with and without cardiovascular disease. 21Astana medicinalyк zhurnaly, Volume 2, Number 125 (2025)Methods. A clinical study of 82 patients with liver cancer was conducted (2022-24). Their physical examination included anthropometric parameters, clinical condition, and laboratory/instrumental parameters e.g. NtProBNP, electrocardiography, echocardiography, cardiovascular diseases. Patients were examined at least three times (before and after chemotherapy, and after 3,6 and 12 months) to ensure a comprehensive evaluation.Results. A study of patients with liver cancer and cardiovascular disease found no significant differences in cardiovascular health. However, heart problems were seen in both groups, suggesting early changes in the heart. NtProBNP levels increased during the 12-month follow-up period in both groups, suggesting its potential value as an independent marker for evaluating patients with liver cancer. There were statistically significant differences in the levels of total and direct bilirubin. Conclusion. Although there were no significant differences in most parameters between groups, the study provided important data on NtProBNP dynamics in patients with liver cancer, which may be useful for future studies and meta-analyses.Keywords: liver cancer, cardiovascular disease, natriuretic peptide, myocardial dysfunction.